The report includes in-depth analysis on our findings of Teva’s Copaxone and Biogen’s Tecfidera, including price and market share data compared to the generic formularies, plan analysis of drugs covered, and more.
DownloadOur content provides subscribers with unique insight and breaking news regarding the most complex mergers and regulatory situations around the world.
InquireOur work combines cutting edge breaking news with in-depth analysis to better inform readers how policy and regulation affects market competition.
Learn MoreOur editorial team reconstructs the policy process to yield market insight for a community of subscribers including government regulators, lawyers, investors, and non-profits.
Learn MoreInvestigative news & analysis on how policy affects market competition
REQUEST A TRIALThe accounting practices of Zynex (ZYXI), a manufacturer of electrotherapy...
May 24, 2023
This article is published in partnership with ProPublica. A key congressional...
May 16, 2023
The FTC is preparing to sue to block Amgen’s (AMGN) proposed $27.8 billion...
May 15, 2023
This week on Second Request, the Hatch-Waxman Act of 1984 laid out a pathway...
Jun 01, 2023
Tommaso Valletti is Professor of Economics at Imperial College Business School...
May 25, 2023
Investigative news & analysis on how policy affects market competition
REQUEST A TRIALWe are an investigative news organization providing our subscribers with detail-oriented reporting on antitrust, merger control, corporate investigations, and energy issues.
“I appreciate the helpful work done by The Capitol Forum. It’s one of the sources I turn to for information about what activity is out there not only in the antitrust space, but also in the consumer protection world.”
“I have become an avid reader of The Capitol Forum because it provides timely in-depth news and analysis of the myriad legal, business, legislative and political factors affecting business developments. I always come away with fresh perspectives that help me advise my clients about current issues.”
“I eagerly read every report from The Capitol Forum and have great admiration for its reporters and editors. I find it to be the single best source of up-to-the-minute coverage and objective in-depth analysis of cutting-edge antitrust news and other critical competition-related developments.”
“The Capitol Forum’s news and analysis is spot on and reflects a perfect mix of investigative reporting, independent research, and expert opinion.”
“The Capitol Forum provides an always interesting and sometimes surprising look under the hood about pending antitrust activities.”
“The Capitol Forum is the only team covering this incredibly important beat. Better yet, their work is deeply intelligent, influential, and almost always right.”
“The Capitol Forum consistently provides timely and sophisticated news and analysis of important M & A transactions. It’s the real deal!”
“The Capitol Forum has been an indispensable resource for me in analyzing regulatory risk affecting companies in my portfolio or watch list.”